Clinical Trial

Sugar Metabolism in Nonalcoholic Fatty Liver Disease

Study Description

Impact of Fructose on Metabolism, Energy Homeostasis and MR Biomarkers in NAFLD

This study will advance several goals of the NIH Action Plan: 1) establish a multidisciplinary team to develop quantitative methodologies and imaging protocols for liver, 2) validate diagnostic criteria and methodologies for imaging in liver in both a cross-sectional and a longitudinal dietary intervention study of patients with NAFLD, 3) create a liver tissue bank with correlative imaging data, 4) develop reliable non-invasive MR markers to distinguish simple steatosis from NASH, and 5) define the dynamic changes in metabolism, energy homeostasis, and MR biomarkers as they relate to fructose-related liver injury.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - intravenous fructose challenge

Patients will be admitted to our Duke Clinical Research Unit (DCRU) at least 12 hours prior to morning intravenous fructose challenge. All patients will have a "standard" meal in order to control for dietary composition and calorie intake prior to intravenous fructose challenge. Patients will be NPO after midnight for morning IV fructose MR biomarker measures. Patients with suspected NAFLD will have a standard of care , liver biopsy followed by , and co-localization of liver biopsy with MR.

Additional Information

Official Study Title

Impact of Fructose on Metabolism, Energy Homeostasis and MR Biomarkers in Nonalcoholic Fatty Liver Disease (NAFLD)

Clinical Trial ID

NCT01930123

ParticipAid ID

QeZzve